Vibostolimab Biosimilar Monoclonal Antibody (TIGIT) for Research

Cat No.: GMP-Bios-ab-620

Pre-Made Vibostolimab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vibostolimab is a TIGIT-targeting (T-cell immunoreceptor with Ig) antibody is being developed by Merck Sharp & Dohme for the treatment of solid tumours such as non-small cell lung cancer, malignant melanoma.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-620-1mg 1mg 618

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Vibostolimab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody
INN Name Vibostolimab
TargetTIGIT
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesMerck
Conditions Approvedna
Conditions ActiveSolid tumours;Non-small cell lung cancer;Malignant melanoma
Conditions Discontinuedna
Development Techna



About target - TIGIT

1. Protein T-cell immunoreceptor with Ig and ITIM domains

2. Gene TIGIT

3. Organism Homo sapiens (Human)

Function
Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.